🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

68Ga-PSMA PET in the Renal Cell Carcinoma

RecruitingNAAges 18 Years - 90 YearsAllXijing Hospital
NCT04987086 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The primary research purpose is to evaluate the diagnostic efficacy of 68Ga-PSMA PET in metastatic lesions of locally advanced and advanced renal cell carcinoma, and to compare with that of enhanced CT. The second purpose is to evaluate whether 68Ga-PSMA PET can change the treatment decision of patients with locally advanced and advanced renal cell carcinoma

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * 2017 AJCC renal cell carcinoma TNM stage III, IV lesions; * In contrast-enhanced CT staging, suspicious metastases were found; * There were no known peripheral or central venous problems; * 68Ga PSMA PET / CT imaging can be performed within 6 weeks after the diagnosis of renal cell carcinoma; * Signed the informed consent form of voluntary participation in clinical trials. Exclusion Criteria: * Age ≤ 18 years old; * Can't stand lying flat in PET / CT examination; * There are contraindications for 68Ga PSMA ligands; * In the past two years, there was a history of other malignant tumors, or according to the doctor's research judgment, complications may occur and affect the normal operation of the test; * Renal function is impaired or hemodialysis is in progress.
💊

What it tests

  • PSMA PET
📍

Where

9 sites
The First Hospital of Lanzhou University
Lanzhou, China
General Hospital of Ningxia Medical University
Yinchuan, China
Qinghai University Affiliated Hospital
Xining, China
Xijing Hospital
Xi'an, China
Weinan Central Hospital
Weinan, China
Shaanxi Provincial People's Hospital
Xi'an, China
Xijing 986 Hospital
Xi'an, China
The Second Affiliated Hospital of Shaanxi University of Chinese Medicine
Xianyang, China

…and 1 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy